B- and T-lymphocyte attenuator

BE0010629ProteinHumansBTLA

Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:12796776, PubMed:14652006, PubMed:15568026, PubMed:18193050). It is acted on by 2 drugs in DrugBank.

Gene name
BTLA
UniProtKB entry
Q7Z6A9Swiss-Prot
Cellular location
Cell membrane
Residues / weight
289 residues · 32,834 Da
Also known as
B- and T-lymphocyte-associated protein

Resolves to

Protein
UniProtQ7Z6A9UniProt nameBTLA_HUMAN
Gene
HGNCHGNC:21087NCBI Gene151888GeneCardsBTLA
Pharmacology
KEGGhsa:151888
Structure
PDB2AW2PDB6NYPPDB8F60
Drugs

What you can answer from here — as of October 31, 2023

2DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
1Clinical trialTrials of drugs acting on it, by phase and status
Sign in
6GO termsFunction, process and component, as structured annotations
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which compounds in development act on B- and T-lymphocyte attenuator, and which indications are they being tested in?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In